- Unique particle-engineering approach improves drug solubility and performance
- Amorphous solid dispersions open opportunities for new small-molecule therapeutics
- Integrated solution from formulation screening to commercial manufacturing
Essen, Germany. Evonik now offers EUDRATEC® SoluFlow, a new microparticle technology to enhance solubility of active pharmaceutical ingredients in oral drug products. This emulsion-based process technology overcomes solubility hurdles that cannot be resolved by existing manufacturing technologies. As more than 70 percent of new small molecules are insoluble, EUDRATEC® SoluFlow therefore enables the development of new oral therapeutics in diverse areas such as cancer, cardiovascular diseases, infectious diseases, and diabetes.
EUDRATEC® SoluFlow complements the Evonik Health Care portfolio of oral drug delivery system solutions which comprises oral excipients such as EUDRAGIT® functional polymers, the ready-to-fill functional capsules EUDRACAPTM, as well as technologies and services to optimize drug performance. Evonik Health Care is part of Nutrition & Care, the life sciences division at Evonik, which aims to increase its share of system solutions from 20 percent today to more than 50 percent by 2030.
“Our new technology opens doors to a wider spectrum of oral drugs by enabling the use of molecules that were previously considered insoluble. We look forward to working with customers to develop oral drugs for better, healthier lives,” said Paul Spencer, head of the product line Drug Delivery & Medical Device Solutions at Evonik’s Health Care business.
EUDRATEC® SoluFlow is a technology and service that turns a poorly soluble drug into a free-flowing powder of the amorphous solid dispersion (ASD). This ASD can easily be compressed into tablets or filled into capsules, reducing the number and complexity of post-processing steps. The unique emulsion-based process uses standard pharma equipment to manufacture uniform microparticles that have a controlled target size and are produced at high yield. Case studies indicate that the solubility enhancement achieved through EUDRATEC® SoluFlow also translates into an improved pharmacokinetic performance of the drugs.
Watch our EUDRATEC® SoluFlow video to learn more
“With this latest innovation to our EUDRATEC® portfolio, we are delighted to help with tough solubility problems and fulfill an unmet need for our pharma partners and their patients,” said Jessica Mueller-Albers, strategic marketing director of the global business segment Oral Drug Delivery Solutions at Evonik’s Health Care business.
EUDRATEC® is Evonik’s platform of oral drug delivery technologies for targeted release. This highly innovative solutions portfolio is being continuously expanded in response to the needs of the pharmaceutical industry. In 2020, Evonik launched EUDRATEC® Fasteric for enteric protection and rapid release in the upper small intestine.
Evonik Health Care is one of the world’s leading CDMOs for complex oral and parenteral drug products that require advanced drug delivery solutions. It is also one of the world’s largest contract manufacturers of active pharmaceutical ingredients (APIs) that require complex chemistry and multiple-step syntheses.
Evonik is one of the world leaders in specialty chemicals. The company is active in more than 100 countries around the world and generated sales of €15 billion and an operating profit (adjusted EBITDA) of €2.38 billion in 2021. Evonik goes far beyond chemistry to create innovative, profitable and sustainable solutions for customers. About 33,000 employees work together for a common purpose: We want to improve life today and tomorrow.
About Nutrition & Care
The focus of the business of the Nutrition & Care division is on health and quality of life. It develops differentiated solutions for active pharmaceutical ingredients, medical devices, nutrition for humans and animals, personal care, cosmetics, and household cleaning. In these resilient end markets, the division generated sales of €3.56 billion in 2021 with about 5,300 employees.
In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.